|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0039593,
umls-concept:C0220825,
umls-concept:C0243044,
umls-concept:C0441766,
umls-concept:C1514300,
umls-concept:C1521725,
umls-concept:C1527262,
umls-concept:C1709518,
umls-concept:C1825534,
umls-concept:C1999216,
umls-concept:C2350808,
umls-concept:C2728259
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-5-13
|
|
pubmed:abstractText |
Alvespimycin (17-DMAG, KOS-1022), a potent small-molecule inhibitor of the protein chaperone Hsp90, is being developed as an anticancer agent because of the multiple Hsp90 client proteins involved in cancer cell growth and survival.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1545-5017
|
|
pubmed:author |
pubmed-author:CarolHernanH,
pubmed-author:HoughtonPeter JPJ,
pubmed-author:KeirStephen TST,
pubmed-author:KolbE AndersEA,
pubmed-author:LockRichardR,
pubmed-author:MarisJohn MJM,
pubmed-author:MortonChristopher LCL,
pubmed-author:PhelpsDoris ADA,
pubmed-author:ReynoldsC PatrickCP,
pubmed-author:SmithMalcolm AMA,
pubmed-author:WuJianrongJ
|
|
pubmed:copyrightInfo |
(c) 2008 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
34-41
|
|
pubmed:dateRevised |
2009-1-12
|
|
pubmed:meshHeading |
pubmed-meshheading:18260120-Animals,
pubmed-meshheading:18260120-Antineoplastic Agents,
pubmed-meshheading:18260120-Benzoquinones,
pubmed-meshheading:18260120-Cell Line, Tumor,
pubmed-meshheading:18260120-Dose-Response Relationship, Drug,
pubmed-meshheading:18260120-Drug Screening Assays, Antitumor,
pubmed-meshheading:18260120-Female,
pubmed-meshheading:18260120-HSP90 Heat-Shock Proteins,
pubmed-meshheading:18260120-Humans,
pubmed-meshheading:18260120-Lactams, Macrocyclic,
pubmed-meshheading:18260120-Mice,
pubmed-meshheading:18260120-Mice, SCID,
pubmed-meshheading:18260120-Neoplasms, Experimental,
pubmed-meshheading:18260120-Transplantation, Heterologous,
pubmed-meshheading:18260120-Tumor Burden
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
|
|
pubmed:affiliation |
Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
